Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)

Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)

Author Introduction

Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)

Li Yuejun, Director of the Clinical Trial Center and Research Director of the Oncology Medical Center at Hunan Provincial Traditional Chinese Medicine Hospital. Medical Doctor, Chief Physician, Master’s Supervisor, and High-level Health Talent in Hunan Province.

Engaged in clinical oncology, research, and teaching for over 10 years. Specializes in multidisciplinary comprehensive treatment of nasopharyngeal carcinoma and malignant tumors of the chest and abdomen. Has successively led four key research projects funded by the National Natural Science Foundation, Hunan Provincial Natural Science Foundation, and Hunan Provincial Administration of Traditional Chinese Medicine. Published 7 papers in SCI journals such as the Journal of Clinical and Translational Hepatology and Drug Design, Development, and Therapy. Participated in the translation and publication of three oncology monographs: Colorectal Cancer, Pancreatic Cancer, and Target Volume Delineation and Field Setting for Conformal and Intensity-Modulated Radiation Therapy.

WELCOME TO YOU

Identification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)ShareIdentification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)CollectIdentification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)ViewIdentification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)LikeIdentification and Management of Adverse Reactions to Antibody-Drug Conjugates (ADCs)

Leave a Comment